Meeting of August 17, 2017

Meeting of May 18, 2017

Meeting of March 20, 2017

Meeting of December 15, 2016

Meeting of September 15, 2016

Meeting of July 14, 2016

Meeting of June 2, 2016

Meeting of May 5, 2016

Meeting of April 7, 2016

Meeting of March 17, 2016

Meeting of March 3, 2016

Meeting of February 4, 2016

Meeting of January 7, 2016

Meeting of December 17, 2015

Meeting of November 5, 2015

Meeting of October 15, 2015

Meeting of October 1, 2015

Testimony

The Drug Formulary Commission invited addiction and pain management experts, patient advocates, and representatives from health plan, medical and pharmacy associations and the pharmaceutical industry to provide testimony to its members at its October 1, 2015, meeting.

The Commission requested for testifiers to provide commentary on the process of developing a draft formulary and how they anticipate that it may impact their respective fields.  In addition, the Commission wanted to hear suggestions on the factors that should be used in the criteria to determine which opiates should be considered an appropriate, therapeutically equivalent substitute to a drug that has been designated as having a heightened level of public health risk.

Chapter 258 of the Acts of 2014 directs the Drug Formulary Commission to consider four factors in determining whether a drug should be identified as a therapeutically equivalent substitute, including:

  1. The efficacy of the potential substitute.
  2. The effectiveness of the drug’s abuse-deterrent properties.
  3. How the placement of the drug as a substitute may impact the patient and/or pharmacy in terms of access.
  4. The cost effectiveness of the drug.

This informational hearing was tailored to provide the Commission members with information that most directly relates to the Commission’s mandates and have set up panels based on these four factors.

Only invited participants were allowed to give remarks at this meeting but any interested parties were able to submit written testimony.  The Commission received the following written testimony.

Meeting of September 8, 2015

Meeting of August 6, 2015


This information is provided by the Drug Control Program within the Department of Public Health.